COMMUNIQUÉS West-GlobeNewswire

ViCentra Announces Commercial Launch of New Smartphone-Controlled Kaleido Automated Insulin Delivery Patch Pump System
12/05/2026
New system combines Kaleido with Diabeloop’s DBLG2 algorithm and Dexcom G7, with first commercial deliveries in Germany and the Netherlands planned for later this summer Enables insulin automation to be controlled [...]
Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections
12/05/2026
Investment led by Jon Moulton supports progression of clinical and preclinical programmes addressing critical-priority pathogens Infex to present results from Phase IIa trial for first-in-class anti-virulence therapy [...]
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes
12/05/2026
Interim results from SIDNEY Phase 2 trial show EO2463 rapidly induced extensive in vivo expansion of B cell target-specific CD8 T-cells Correlation established between EO2463-induced and B cell target-specific CD8 T- [...]
Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity
12/05/2026
Early responders (15% or more weight loss after 24 weeks) to the higher dose of Wegovy ® (semaglutide 7.2 mg) achieved on average 27.7% mean weight loss at week 72 in the STEP UP trial 1 Participants treated with the [...]
Coloplast A/S - Announcement no. 05/2026 - Interim Financial Report, H1 2025/26
12/05/2026
2025/26 Interim financial results, H1 2025/26 1 October 2025 - 31 March 2026 Coloplast delivered Q2 organic growth of 6% and 6% EBIT growth 1 in constant currencies. Strong quarter in Chronic Care and Interventional [...]
Coloplast A/S - Announcement no. 05/2026 - Interim Financial Report, H1 2025/26
12/05/2026
2025/26 Interim financial results, H1 2025/26 1 October 2025 - 31 March 2026 Coloplast delivered Q2 organic growth of 6% and 6% EBIT growth 1 in constant currencies. Strong quarter in Chronic Care and Interventional [...]
BioPorto A/S to host an investor webcast on the results for the first quarter of 2026
12/05/2026
May 12, 2026 News release BioPorto A/S to h ost an investor webcast on the results for the first quarter of 202 6 COPENHAGEN, DENMARK, May 12, 2026 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR [...]
Q1 2026 Update: Tecan on track with low-single-digit local currency growth in Q1; full-year 2026 outlook confirmed
12/05/2026
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q1 2026 Update: Tecan on track with low-single-digit local currency growth in Q1; full-year 2026 outlook confirmed Männedorf, [...]
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
12/05/2026
Elecsys® pTau217 is the first blood test for Alzheimer’s disease pathology with a single ‑ assay design, intended to rule in and rule out amyloid pathology across primary and secondary care, offering faster diagnosis [...]
Rapid Nutrition Extends AI-Powered Agentic Platform to Consumer Ecosystem Following Investor Rollout
12/05/2026
LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext Growth: ALRPD ), a global HealthTech company advancing wellness through evidence-based, personalized nutrition solutions, today announced the [...]
Gala Health GLP-1 Compounded and Branded Weight Loss Medication Options with Real Doctor Support
12/05/2026
How Gala GLP-1 Compounded Semaglutide, Tirzepatide, and Microdosing Options Work for Prescription Weight Management Without Insurance in 2026 Wilmington, Delaware, May 11, 2026 (GLOBE NEWSWIRE) -- Compounded medications [...]
Enlitic’s Ensight Goes Live at RHCNZ, Advancing Radiology Workflow Efficiency in New Zealand
12/05/2026
LOVELAND, Colo., May 11, 2026 (GLOBE NEWSWIRE) -- Enlitic, a global leader in radiology and imaging data, today announced the successful go-live of its Ensight platform at RHCNZ Medical Imaging Group (RHCNZ), New [...]
Delos Capital and AP Biosciences Inc. Launch Collaboration to Create New Biotech Companies Focused on Next-Generation Antibodies
12/05/2026
Partnership combines venture creation and biologics discovery to accelerate novel medicines through human clinical proof of concept First-of-its-kind collaboration between a specialist biotech venture firm and a [...]
Sotera Health Announces Secondary Offering of Common Stock
11/05/2026
CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 31,838,253 shares of its common stock, par value $0. [...]
Sanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited)
11/05/2026
Net Revenue Growth of 19% and Net Profitability from Continuing Operations of $0.04 Per Fully Diluted Share for the Quarter FORT WORTH, TX, May 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” “Sanara MedTech [...]
Cellectis Reports Financial Results for the First Quarter 2026
11/05/2026
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) Pivotal Phase 2 first interim analysis expected in Q4 2026 BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 trial) Full Phase 1 [...]
Health Catalyst Reports First Quarter 2026 Results
11/05/2026
SALT LAKE CITY, May 11, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today [...]
Cellectis publie ses résultats financiers du premier trimestre 2026
11/05/2026
Phase 2 pivot évaluant lasmé-cel dans la LAL-B en rechute ou réfractaire (étude BALLI-01) Analyse intermédiaire de phase 2 pivot attendue en Q4 2026 Dépôt de demande d'autorisation de mise sur le marché (BLA) prévu en [...]
STERIS Announces Financial Results for Fiscal 2026 Fourth Quarter and Full Year
11/05/2026
Full year fiscal 2026 revenue from continuing operations increased 9%; constant currency organic revenue growth was 7% Full year fiscal 2026 as reported diluted EPS from continuing operations increased to $7.93; [...]

Pages